Comparative Pharmacology
Head-to-head clinical analysis: AZMIRO versus LACOSAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMIRO versus LACOSAMIDE.
AZMIRO vs LACOSAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Oral or IV: 50 mg twice daily initially; increase by 50 mg twice daily weekly to maintenance 100-200 mg twice daily. Maximum 200 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Clinical Note
moderateLacosamide + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Delavirdine
Terminal elimination half-life is approximately 13 hours (range 12–16 hours) in adults. Steady state achieved after 3 days with BID dosing.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Renal: approximately 95% (40% unchanged, remainder as O-desmethyl metabolite). Fecal: <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Delavirdine can be increased when it is combined with Lacosamide."